
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5813505/publications.pdf Version: 2024-02-01



AUSAL HADT

#	Article	IF	CITATIONS
1	Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics, 2015, 47, 979-986.	21.4	1,965
2	The gut microbiota and host health: a new clinical frontier. Gut, 2016, 65, 330-339.	12.1	1,719
3	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	1.3	1,324
4	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nature Genetics, 2017, 49, 256-261.	21.4	943
5	European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66, 569-580.	12.1	793
6	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
7	Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer. World Journal of Gastroenterology, 2016, 22, 3117.	3.3	351
8	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut, 2014, 63, 1381-1392.	12.1	317
9	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 2019, 68, 2111-2121.	12.1	290
10	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
11	The use of faecal microbiota transplant as treatment for recurrent or refractory <i>Clostridium difficile</i> infection and other potential indications: joint British Society of Gastroenterology (BSC) and Healthcare Infection Society (HIS) guidelines. Gut, 2018, 67, 1920-1941.	12.1	248
12	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2020, 69, 984-990.	12.1	232
13	Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview. American Journal of Gastroenterology, 2015, 110, 1022-1034.	0.4	227
14	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 785-792.	8.1	196
15	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	1.3	185
16	Anti-TNF Therapy in Crohn's Disease. International Journal of Molecular Sciences, 2018, 19, 2244.	4.1	177
17	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nature Genetics, 2017, 49, 186-192.	21.4	153
18	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153

AILSA L HART

#	Article	IF	CITATIONS
19	Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 548-558.	8.1	143
20	A blood-based prognostic biomarker in IBD. Gut, 2019, 68, 1386-1395.	12.1	132
21	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	7.4	129
22	The gut virome: the â€~missing link' between gut bacteria and host immunity?. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481983662.	3.2	127
23	Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer. American Journal of Gastroenterology, 2015, 110, 1461-1471.	0.4	118
24	Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut, 2019, 68, 414-422.	12.1	117
25	Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for crohn's perianal fistulas. Inflammatory Bowel Diseases, 2012, 18, 1825-1834.	1.9	114
26	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. The Lancet Gastroenterology and Hepatology, 2021, 6, 218-224.	8.1	111
27	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	8.1	100
28	Topical tacrolimus in the treatment of perianal Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 245-253.	1.9	98
29	Evolutionary history of human colitis-associated colorectal cancer. Gut, 2019, 68, 985-995.	12.1	97
30	Use of Probiotics in the Treatment of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2003, 36, 111-119.	2.2	94
31	Determining Predictors for Intra-abdominal Septic Complications Following Ileocolonic Resection for Crohn's DiseaseConsiderations in Pre-operative and Peri-operative Optimisation Techniques to Improve Outcome. Journal of Crohn's and Colitis, 2015, 9, 483-491.	1.3	92
32	Ulcerative colitis: an update. Clinical Medicine, 2021, 21, 135-139.	1.9	87
33	What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance. Journal of Crohn's and Colitis, 2017, 11, 204-211.	1.3	83
34	The Effect of Vitamin D on Intestinal Inflammation and Faecal Microbiota in Patients with Ulcerative Colitis. Journal of Crohn's and Colitis, 2018, 12, 963-972.	1.3	78
35	Bacteroides thetaiotaomicron-derived outer membrane vesicles promote regulatory dendritic cell responses in health but not in inflammatory bowel disease. Microbiome, 2020, 8, 88.	11.1	76
36	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open″abel, longâ€ŧerm extension study with up to 7.0Âyears of treatment. Alimentary Pharmacology and Therapeutics, 2022, 55, 464-478.	3.7	73

#	Article	IF	CITATIONS
37	Compartment-specific immunity in the human gut: properties and functions of dendritic cells in the colon versus the ileum. Gut, 2016, 65, 256-270.	12.1	72
38	Developing a core outcome set for fistulising perianal Crohn's disease. Gut, 2019, 68, 226-238.	12.1	64
39	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Digestive Diseases, 2019, 37, 266-283.	1.9	63
40	Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial. Gut, 2019, 68, 1774-1780.	12.1	56
41	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. Journal of Crohn's and Colitis, 2020, 14, 1037-1048.	1.3	55
42	Endoscopic Dilatation of Crohn's Anastomotic Strictures is Effective in the Long Term, and Escalation of Medical Therapy Improves Outcomes in the Biologic Era. Journal of Crohn's and Colitis, 2016, 10, 1172-1178.	1.3	51
43	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease—the Unmet Needs. Journal of Crohn's and Colitis, 2016, 10, 758-765.	1.3	49
44	The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481882225.	3.2	49
45	Clinical Trials in Ulcerative Colitis: A Historical Perspective. Journal of Crohn's and Colitis, 2015, 9, 580-588.	1.3	48
46	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
47	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilarâ€treated IBD patients. Alimentary Pharmacology and Therapeutics, 2019, 49, 1181-1187.	3.7	42
48	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. Trials, 2015, 16, 366.	1.6	40
49	The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSC) and Healthcare Infection Society (HIS) guidelines. Journal of Hospital Infection, 2018, 100, S1-S31.	2.9	38
50	METRIC (MREnterography or ulTRasound in Crohn's disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over. BMC Gastroenterology, 2014, 14, 142.	2.0	36
51	Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. Frontline Gastroenterology, 2016, 7, 122-128.	1.8	36
52	Standardising assessment and documentation of pouchoscopy. Frontline Gastroenterology, 2018, 9, 309-314.	1.8	35
53	International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflammatory Bowel Diseases, 2021, 27, 1942-1953.	1.9	30
54	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointestinal Endoscopy, 2018, 88, 360-369.e2.	1.0	29

#	Article	IF	CITATIONS
55	Review of local injection of anti-TNF for perianal fistulising Crohn's disease. International Journal of Colorectal Disease, 2017, 32, 1539-1544.	2.2	28
56	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	12.1	28
57	Chemokine (C-C Motif) Receptor 2 Mediates Dendritic CellÂRecruitment to the Human Colon but Is Not ResponsibleÂforÂDifferences Observed in Dendritic CellÂSubsets,ÂPhenotype, and Function Between the ProximalÂandÂDistal Colon. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 22-39.e5.	4.5	27
58	Predicting Colorectal Cancer Occurrence in IBD. Cancers, 2021, 13, 2908.	3.7	26
59	How Should Pain, Fatigue, and Emotional Wellness Be Incorporated Into Treatment Goals for Optimal Management of Inflammatory Bowel Disease?. Gastroenterology, 2022, 162, 1439-1451.	1.3	25
60	The role of multimodal treatment in Crohn′s disease patients with perianal fistula: a multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2018, 48, 941-950.	3.7	24
61	Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 735-743.	1.3	24
62	Clinical trials in luminal Crohn's disease: A historical perspective. Journal of Crohn's and Colitis, 2014, 8, 1339-1350.	1.3	23
63	Defining the optimal design of the inflammatory bowel disease multidisciplinary team: results from a multicentre qualitative expert-based study. Frontline Gastroenterology, 2015, 6, 290-297.	1.8	23
64	Long-term follow-up of the use of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis. Frontline Gastroenterology, 2018, 9, 154-158.	1.8	23
65	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281.	8.1	23
66	Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 26-48.	3.7	23
67	Systematic review with metaâ€analysis: IBDâ€associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present). Alimentary Pharmacology and Therapeutics, 2020, 52, 5-19.	3.7	22
68	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. Digestive and Liver Disease, 2020, 52, 138-142.	0.9	21
69	The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis. Nutrients, 2021, 13, 1780.	4.1	21
70	A Systematic Review: The Management and Outcomes of Ileal Pouch Strictures. Journal of Crohn's and Colitis, 2018, 12, 369-375.	1.3	20
71	Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1491-1502.	3.7	20
72	International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2020, 14, S780-S784.	1.3	20

#	Article	IF	CITATIONS
73	Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 1475-1492.	1.3	20
74	The Incidence and Prevalence of Human Papilloma Virus–associated Cancers in IBD. Inflammatory Bowel Diseases, 2021, 27, 34-39.	1.9	19
75	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology and Hepatology, 2022, 7, 254-261.	8.1	18
76	Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. The Lancet Gastroenterology and Hepatology, 2022, 7, 576-584.	8.1	17
77	Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989103.	3.2	15
78	Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. Inflammatory Bowel Diseases, 2021, 27, 1096-1106.	1.9	15
79	Incidence and Long-term Implications of Prepouch Ileitis: An Observational Study. Diseases of the Colon and Rectum, 2018, 61, 472-475.	1.3	14
80	Chronic pain in patients with inflammatory bowel disease. Pain, 2021, 162, 2466-2471.	4.2	14
81	A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population. Digestive Diseases and Sciences, 2018, 63, 3049-3057.	2.3	13
82	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. Journal of Crohn's and Colitis, 2020, 14, 1769-1776.	1.3	13
83	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Annals of Gastroenterology, 2020, 33, 170-177.	0.6	13
84	Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. Scandinavian Journal of Gastroenterology, 2018, 53, 1051-1058.	1.5	12
85	Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. Gut, 2022, 71, 705-715.	12.1	12
86	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. Autoimmunity Reviews, 2021, 20, 102849.	5.8	12
87	Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study. Frontline Gastroenterology, 2018, 9, 234-240.	1.8	11
88	Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. Trials, 2021, 22, 516.	1.6	11
89	Biofeedback in patients with ileoanal pouch dysfunction: a specialist centre experience. Scandinavian Journal of Gastroenterology, 2018, 53, 665-669.	1.5	10
90	Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease. Digestive Diseases and Sciences, 2021, 66, 2700-2711.	2.3	10

#	Article	IF	CITATIONS
91	Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study. Health Technology Assessment, 2019, 23, 1-162.	2.8	10
92	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment® ^{MMX®}) for active, mildâ€ŧoâ€moderate ulcerative colitis. United European Gastroenterology Journal, 2019, 7, 1171-1182.	3.8	9
93	Current review of the management of fistulising perianal Crohn's disease. Frontline Gastroenterology, 2021, 12, 515-523.	1.8	9
94	Clinician Administered and Self-Report Survey Both Effective for Identifying Fecal Incontinence in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2021, 66, 2024-2031.	2.3	9
95	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	4.4	9
96	Faecal incontinence intervention study (FINS): self-management booklet information with or without nurse support to improve continence in people with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials, 2015, 16, 444.	1.6	8
97	Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. Journal of Crohn's and Colitis, 2022, 16, 922-930.	1.3	8
98	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterology, 2016, 3, e000092.	2.7	7
99	Faecal microbiota transplantation as a treatment for inflammatory bowel disease: a national survey of adult and paediatric gastroenterologists in the UK. Frontline Gastroenterology, 2018, 9, 250-255.	1.8	7
100	Biological therapy for the treatment of prepouch ileitis: a retrospective observational study from three centers. Clinical and Experimental Gastroenterology, 2018, Volume 11, 461-465.	2.3	7
101	A proposed tailored investigational algorithm for women treated for gynaecological cancer with long-term gastrointestinal consequences. Supportive Care in Cancer, 2020, 28, 4881-4889.	2.2	7
102	IBD: reproductive health, pregnancy and lactation. Frontline Gastroenterology, 2015, 6, 38-43.	1.8	6
103	In Patients With Perianal Crohn's Fistulas, What Are the Outcomes When â€~Radiological Healing' Is Achieved? Does Radiological Healing of Perianal Crohn's Fistulas Herald the Time Point for Stopping a Biologic?. Journal of Crohn's and Colitis, 2017, 11, 1506-1506.	1.3	6
104	Does the Internet promote the unregulated use of fecal microbiota transplantation: a potential public health issue?. Clinical and Experimental Gastroenterology, 2018, Volume 11, 179-183.	2.3	6
105	Are we addressing the top 10 research priorities in IBD?. Frontline Gastroenterology, 2021, 12, 564-569.	1.8	6
106	Vitamin D and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 459-460.	1.9	5
107	What is the patient's and multidisciplinary team's perspective on telephone clinics?. British Journal of Health Care Management, 2021, 27, 26-31.	0.2	5
108	The pouch behaving badly: management of morbidity after ileal pouch–anal anastomosis. Colorectal Disease, 2021, 23, 1193-1204.	1.4	5

#	Article	IF	CITATIONS
109	Meeting update: faecal microbiota transplantation––bench, bedside, courtroom?. Frontline Gastroenterology, 2018, 9, 45-48.	1.8	4
110	How Quickly Do Inflammatory Bowel Disease Medications Really Work?. Clinical Gastroenterology and Hepatology, 2019, 17, 34-35.	4.4	4
111	Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ Open, 2021, 11, e043921.	1.9	4
112	The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink. Annals of Gastroenterology, 2020, 33, 500-507.	0.6	4
113	Strategies to Distinguish Perianal Fistulas Related to Crohn's Disease From Cryptoglandular Disease: Systematic Review With Meta-Analysis. Inflammatory Bowel Diseases, 2021, , .	1.9	4
114	Pilot study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas. International Journal of Surgery, 2017, 41, 127-133.	2.7	3
115	Volume assessment magnetic resonance imaging technique for monitoring perianal Crohn's fistulas. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481879360.	3.2	3
116	Management of inflammatory bowel disease associated colonic dysplasia: factors predictive of patient choice and satisfaction. Colorectal Disease, 2021, 23, 882-893.	1.4	3
117	Perception of Cancer Risk and Management Practice for Colitis-associated Dysplasia Is Influenced by Colonoscopy Experience and Workplace Affiliation: Results of an International Clinician Survey. Journal of Crohn's and Colitis, 2022, 16, 39-48.	1.3	3
118	Medical-surgical Combined Approach in Perianal Fistulizing Crohn's Disease (CD): Doing it Together. Current Drug Targets, 2019, 20, 1373-1383.	2.1	3
119	Observational data from the adalimumab postâ€marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. United European Gastroenterology Journal, 2022, 10, 485-495.	3.8	3
120	Republished curriculum based clinical review: IBD: reproductive health, pregnancy and lactation. Postgraduate Medical Journal, 2015, 91, 230-235.	1.8	2
121	A review of endoscopic balloon dilatation techniques for treating Crohn's strictures: time to standardise therapy. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1101-1107.	3.0	2
122	Quantitative Magnetic Resonance Imaging in Perianal Crohn's Disease at 1.5 and 3.0 T: A Feasibility Study. Diagnostics, 2021, 11, 2135.	2.6	2
123	Assessing online information sources on ileal pouch-anal anastomosis. Gastrointestinal Nursing, 2017, 15, 20-22.	0.1	1
124	Editorial: how safe is it to administer the BCG vaccination to babies exposed to antiâ€TNFα medications antenatally?. Alimentary Pharmacology and Therapeutics, 2019, 50, 1239-1239.	3.7	1
125	Patient perceptions of joint medical-surgical assessment in a tertiary referral clinic for inflammatory bowel disease. British Journal of Health Care Management, 2021, 27, 146-151.	0.2	1
126	Prognostic factors associated with unhealed perineal wounds postâ€proctectomy for perianal Crohn's disease: a twoâ€centre study. Colorectal Disease, 2021, 23, 2091-2099.	1.4	1

AILSA L HART

#	Article	IF	CITATIONS
127	A Multidisciplinary Approach to Rectal Cancer Treatment in Ulcerative Colitis Results in High Rate of Restorative Minimally Invasive Surgery. Journal of Crohn's and Colitis, 2022, 16, 244-250.	1.3	1
128	Management of Perianal Crohnâ \in ^{IM} s Disease in the Biologic Era. , 2017, , 1-27.		1
129	The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD. Clinics in Colon and Rectal Surgery, 2022, 35, 021-031.	1.1	1
130	Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Alimentary Pharmacology and Therapeutics, 2021, 53, 342-343.	3.7	1
131	Evaluation of an inflammatory bowel disease service to drive sustainable improvement. British Journal of Health Care Management, 2018, 24, 476-478.	0.2	0
132	PTU-099â€Evaluation to support service improvement for patients with inflammatory bowel disease at ST mark's hospital. , 2018, , .		0
133	Twenty years of biological therapy in an patient with IBD. BMJ Case Reports, 2018, 2018, bcr-2017-221994.	0.5	Ο
134	Commentary: safety of antiâ€TNF use in pregnancy. Alimentary Pharmacology and Therapeutics, 2020, 51, 205-206.	3.7	0
135	HPV-related Cancers in Inflammatory Bowel Disease: Association Not Yet Causation. Inflammatory Bowel Diseases, 2020, 26, e102-e102.	1.9	Ο
136	Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2021, 8, 1-88.	0.7	0